Lipovexa Logo

About

Lipovexa develops innovative pharmaceutical and nutraceutical solutions for metabolic diseases, with a focus on obesity, diabetes and related liver disorders.

Its pharmaceutical pipeline includes proprietary small-molecule programmes targeting key metabolic pathways, including GPR119 agonists and dual GLP-1/GIP secretagogue approaches aimed at improving glucose regulation, metabolic control and weight management.

In parallel, Lipovexa is advancing a nutraceutical asset designed to support metabolic health and long-term weight management, including the maintenance of weight loss following GLP-1-based therapies.

Lipovexa

Founded

2024